Prelude Therapeutics To Participate in Two Upcoming
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a
Globe Newswire9-02-2023, 21:11
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab) 5-04-2024, 12:00